Clinical Trials | December 30, 2025
One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
The study met its primary endpoint with flying colors
The study met its primary endpoint with flying colors
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Subscribe To Our Newsletter & Stay Updated
